Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Cushing Syndrome I: Introduction

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Cushing Syndrome II: Pathophysiology

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Virtual GERAS DANcing for Cognition Exercise (DANCE) for older adults at home: a randomized feasibility trial.

Pilot and feasibility studies·2026

Same author

An explainable machine learning approach to predict fragility fractures and the identification of important features.

Scientific reports·2026

Same author

Augmented Reality for Balance Rehabilitation in Older Persons: A Scoping Review.

Canadian geriatrics journal : CGJ·2026

Same author

Cognitive Groove community-based rehabilitation for older adults: study protocol for a multisite parallel randomized controlled trial.

Trials·2026

Same author

Ordinal GWAS analysis of the frailty phenotype identified a novel locus at 12q22 that underscores the role of the neurological and immune systems.

npj aging·2026

Same author

The crossroads between osteosarcopenia and intrinsic capacity-a narrative review.

The journals of gerontology. Series A, Biological sciences and medical sciences·2026

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Glucocorticoid-induced osteoporosis.

Courtney C Kennedy¹, Alexandra Papaioannou, Jonathan D Adachi

¹Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Women'S Health (London, England)

|October 7, 2009

Summary

Glucocorticoids can cause bone loss and fractures, leading to osteoporosis. Effective management strategies can prevent or reduce these risks in patients undergoing glucocorticoid therapy.

Area of Science:

Endocrinology
Bone Metabolism
Pharmacology

Background:

Glucocorticoids are essential medications for various diseases.
A significant side effect is glucocorticoid-induced osteoporosis (GIO).
Fractures can occur early, even with low-dose glucocorticoid use.

Purpose of the Study:

To provide an overview of glucocorticoid-induced osteoporosis.
To outline strategies for recognizing, preventing, and treating GIO.
To address management in pre- and postmenopausal women on glucocorticoid therapy.

Main Methods:

Literature review of current evidence on GIO.
Analysis of clinical practice guidelines for GIO management.
Synthesis of information on risk factors, diagnosis, and treatment.

Related Experiment Videos

Last Updated: Jun 19, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Main Results:

Glucocorticoid therapy poses a significant risk for osteoporosis and fractures.
Early intervention and effective management can mitigate bone loss.
GIO is often underdiagnosed and undertreated despite available guidelines.

Conclusions:

Glucocorticoid-induced osteoporosis is a serious complication requiring proactive management.
Early recognition and timely treatment are crucial for preventing fractures.
Comprehensive management strategies are vital for patients on glucocorticoid therapy.